Disease details

What is ALS?

Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease or Motor Neurone Disease (MND) is a progressive, fatal neurological disease. The disorder belongs to a class of disorders known as motor neuron diseases.

ALS occurs when specific nerve cells in the brain and spinal cord that control voluntary movement gradually degenerate. The loss of these motor neurons causes the muscles under their control to weaken and waste away, leading to paralysis.

ALS manifests itself in different ways, depending on which muscles weaken first. Symptoms may include tripping and falling, loss of motor control in hands and arms, difficulty speaking, swallowing and/or breathing, persistent fatigue, and twitching and cramping, sometimes quite severely. ALS strikes in mid-life. Men are about one-and-a-half times more likely to have the disease as women.

Latest ALS medical news

Wed, 29 Mar 2017 00:00:00 PDT
'Groundbreaking' technology enables quadriplegic man to move his limbs
 
Using neuroprosthetic technology, scientists have enabled a man who had been quadriplegic for 8 years to move his limbs and perform daily tasks.
Tue, 28 Mar 2017 00:00:00 PDT
Scientists discover shared genetic origin for ALS/MND and schizophrenia
 
Researchers have shown for the first time that Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease (MND) and schizophrenia have a shared genetic origin, indicating that the...
Thu, 23 Mar 2017 00:00:00 PDT
Researchers identify potential treatment for type of muscle and brain degenerative disease
 
UCLA researchers have discovered the molecular basis of, and identified potential treatment for, an incurable disease known as inclusion body myopathy, Paget disease with frontotemporal dementia...
Mon, 20 Mar 2017 00:00:00 PDT
New toxic pathway identified for protein aggregates in neurodegenerative disease
 
Led by professor Ludo Van Den Bosch (VIB-KU Leuven), scientists from Belgium, the UK and the US have identified new processes that form protein "clumps" that are characteristic of amyotrophic...
Wed, 08 Mar 2017 09:00:00 PDT
Caffeine may ward off dementia by boosting protective enzyme
 
Researchers have uncovered a number of compounds - including caffeine - that boost production of the enzyme NMNAT2, which may protect against dementia.
Tue, 07 Mar 2017 08:00:00 PDT
Red wine compound found to slow down neural aging in mice
 
New study shows that resveratrol reduces age-induced deterioration of neuromuscular synapses in mice. Anti-diabetes drug may also slow down muscular aging.
Thu, 02 Mar 2017 06:00:00 PDT
Molecular structure of the cell nucleoskeleton revealed for the first time
 
Using 3D electron microscopy, structural biologists from the University of Zurich succeeded in elucidating the architecture of the lamina of the cell nucleus at molecular resolution for the first...
Mon, 27 Feb 2017 00:00:00 PDT
Meditation benefits patients with ALS
 
An eight-week mindfulness-based meditation program led to improved quality of life and psychological well-being in clinical trial of patients with amyotrophic lateral sclerosis (ALS).
Wed, 15 Feb 2017 00:00:00 PDT
Children of patients with C9orf72 mutations are at a greater risk of frontotemporal dementia or ALS at a younger age
 
The most common genetic cause of the brain diseases frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) is a mutation in the C9orf72 gene.
Wed, 15 Feb 2017 00:00:00 PDT
Dietary supplement could improve heart health
 
Dietary intervention could benefit heart health in those with muscular dystrophy. That's according to new research published in Experimental Physiology.
Mon, 13 Feb 2017 00:00:00 PDT
Researchers show how Lou Gehrig's disease progression could be delayed
 
A team of biomedical scientists has identified a molecule that targets a gene known to play a critical role in the rapid progression of amyotrophic lateral sclerosis (ALS), sometimes known as Lou...
Fri, 10 Feb 2017 07:00:00 PDT
Gene discovery suggests new type of congenital muscular dystrophy
 
New study finds that mutations in INPP5K gene cause a new type of congenital muscular dystrophy with short stature, cataracts, and intellectual disability.
Fri, 10 Feb 2017 06:00:00 PDT
FDA approves drug to treat Duchenne muscular dystrophy
 
The U.S. Food and Drug Administration has approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic...
Wed, 01 Feb 2017 00:00:00 PDT
Breakthrough technology enables communication in late-stage ALS
 
A brain-computer interface has been found to enable people in a completely locked-in state in the late stages of ALS to communicate meaningfully.
Tue, 31 Jan 2017 00:00:00 PDT
Rebalancing gut microbiome lengthens survival in mouse model of ALS
 
A bacterial by-product known to be important in maintaining gut health may slow the progression of amyotrophic lateral sclerosis, or ALS - a progressive, neurodegenerative disease.
Thu, 26 Jan 2017 00:00:00 PDT
Development of ALS syndromes caused by impairment of nuclear-cytoplasmic transport in motor neurons
 
A team of scientists led by Dr. Paulo A Ferreira at Duke University Medical Center and whose work was supported by the National Institutes of Health, has found evidence that derailing the transport...
Thu, 26 Jan 2017 00:00:00 PDT
Scientists stop and reverse Alzheimer's-related brain damage in mice
 
Scientists have found a molecule that restores normal levels of a protein responsible for Alzheimer's disease; tests were performed on mice and monkeys.
Wed, 11 Jan 2017 00:00:00 PDT
Study identifies potential drug targets for muscular dystrophy treatments
 
Myotonic dystrophy type I (MD1) is a common form of muscular dystrophy associated with muscle wasting, weakness, and myotonia.
Tue, 13 Dec 2016 06:00:00 PDT
TSRI scientists devise new approaches to personalized medicines
 
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed broad methods to design precision medicines against currently incurable diseases caused by RNA.
Tue, 13 Dec 2016 02:00:00 PDT
12-month edaravone clinical study data in ALS presented at the 27th international symposium on als/mnd
 
Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President & Representative Director, CEO: Dr.
Mon, 12 Dec 2016 08:00:00 PDT
Football players 'not at higher risk of neurodegenerative disease'
 
Given that football players have a high risk of head trauma, a new study investigates if this also puts them at risk of brain degenerative disease.
Fri, 09 Dec 2016 09:00:00 PDT
Study investigates how to turn stem cells into motor neurons
 
A team of researchers investigates details of the cellular mechanisms involved in transforming a stem cell into a motor neuron, through direct programming.
Wed, 07 Dec 2016 00:00:00 PDT
New drug might halt the progress of neurodegenerative disease
 
Spinal muscular atrophy type 1 kills most infants by their second birthday. A new drug has shown positive results against the disease in young patients.
Mon, 28 Nov 2016 06:00:00 PDT
Screening newborns for muscle wasting condition not recommended, UK
 
The UK National Screening Committee (UK NSC) finds babies should not be screened for Duchenne muscular dystrophy.
Tue, 22 Nov 2016 08:00:00 PDT
Muscular dystrophy: Cancer drug may boost muscle strength for some patients
 
Researchers reveal how the cancer drug sunitinib may reduce muscle weakness for patients with facioscapulohumeral dystrophy - a form of muscular dystrophy.